Phase I/II trial of HIV-1 hyperimmune globulin for the prevention of HIV-1 vertical transmission in Uganda

AIDS

Volumn 16, Issue 10, 2002, Pages 1391-1400

  Guay, Laura A ^a   Musoke, Philippa ^a,b   Hom, David L ^a,c   Nakabiito, Clemensia ^a,b   Bagenda, Danstan ^a,b   Fletcher, Courtney V ^a,d   Marum, Lawrence H ^a,e   Fowler, Mary Glenn ^a,f   Falksveden, Lars G ^a,g   Wahren, Britta ^a,g   Kataaha, Peter ^a,h   Wigzell, Hans ^a,i   Mmiro, Francis A ^a,b   Brooks Jackson, J ^a,j  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b MAKERERE UNIVERSITY   (Uganda)

^c RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^f CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^g SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^h MINISTRY OF HEALTH   (Uganda)

ⁱ KAROLINSKA INSTITUTE   (Sweden)

^j JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Africa; HIV hyperimmune globulin; HIV vertical transmission; Mother to child transmission; Uganda

Indexed keywords

ACETYLSALICYLIC ACID; CHLOROQUINE; DIPHENHYDRAMINE; HYPERIMMUNE GLOBULIN; VIRUS DNA; VIRUS RNA; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IMMUNOGLOBULIN;

ADULT; ARTICLE; BLOOD BANK; BREAST FEEDING; CAUSE OF DEATH; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FEMALE; FEVER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NEWBORN INFECTION; NEWBORN MORTALITY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PREGNANCY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UGANDA; VERTICAL TRANSMISSION; VIRUS INFECTION; VIRUS TRANSMISSION; DISEASE TRANSMISSION; HALF LIFE TIME; METABOLISM; NEWBORN; PREGNANCY COMPLICATION;

ADULT; DISEASE TRANSMISSION, VERTICAL; FEMALE; HALF-LIFE; HIV ANTIBODIES; HIV INFECTIONS; HUMAN; IMMUNOGLOBULINS, INTRAVENOUS; INFANT, NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; SUPPORT, U.S. GOV'T, P.H.S.; UGANDA; HUMANS;

EID: 0037024759     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200207050-00011     Document Type: Article

References (44)

1. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: A randomised controlled trial
2. Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Cote d'Ivoire: A randomised trial
3. 6-Month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Cote d'Ivoire and Burkina Faso: A double-blind placebo-controlled multicentre trial
4. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomized trial
5. Effect of breastfeeding and formula feeding on transmission of HIV-1: A randomized clinical trial
6. Prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HbeAg by administration of hepatitis-B vaccine and hepatitis-B immunoglobulin: Double blind randomized placebo controlled study
7. Intravenous gamma-globulin in pregnancy: A review
8. Role of immunoglobulin therapy in neonatal infections: Where we stand today
9. Efficacy of hepatitis B immune globulin for prevention of perinatal transmission of the hepatitis B virus carrier state: Final report of a randomized double-blind, placebo-controlled trial
10. sm infection by passive immunization in cynomolgous monkeys
11. Passive immunization of newborn rhesus macaques prevents oral simian immunodeficiency virus infection
12. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies
13. Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12
14. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies
15. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody
16. Protection of neonatal kittens against feline immunodeficiency virus infection with passive maternal antiviral antibodies
17. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection
18. Prevention of HIV infection by passive immunization with HIV immunoglobulin
19. Passive immunotherapy in the treatment of advanced human immunodeficiency virus infection
20. Effects of passive immunization in patients with AIDS related complex and AIDS
21. Passive immunoneutralisation of human immunodeficiency virus in patients with advanced AIDS
22. Passive hyperimmune plasma therapy in the treatment of acquired immunodeficiency syndrome: Results of a 12-month multicenter double-blind controlled trial
23. Passive immunotherapy in AIDS: A randomized trial of serial human immunodeficiency virus-positive transfusions of plasma rich in p24 antibodies versus transfusions of seronegative plasma
24. Immunological and virological interactions in patients receiving passive immunotherapy with HIV-1 neutralizing monoclonal antibodies
25. Preparation and characterization of an intravenous solution of IgG from human immunodeficiency virus-seropositive donors
26. Inactivation of viruses in plasma on treatment with tri(N-butyl) phosphate (TNBP) detergent mixtures
27. Ion exchange and polyethylene glycol precipitation of immunoglobulin G
28. Serological markers in early states of human immunodeficiency virus infection in hemophiliacs
29. Nucleotide sequence of a Ugandan HIV-1 provirus reveals genetic diversity from other HIV-1 isolates
30. Ugandan HIV-1 V3 loop sequences closely related to the U.S./European Consensus
31. Rapid and sensitive viral culture method for human immunodeficiency virus type 1
32. Efficiencies of four versions of the AMPLICOR HIV-1 MONITOR test for quantification of different subtypes of human immunodeficiency virus type 1
33. Pharmacokinetics of hyperimmune anti-human immunodeficiency virus immunoglobulin in persons with AIDS
34. Safety and pharmacokinetics of hyperimmune anti-human immunodeficiency virus (HIV) immunoglobulin administered to HIV-infected pregnant women and their newborns
35. Presence of maternal antibodies to human immunodeficiency virus 1 envelope glycoprotein correlates with the uninfected status of children born to seropositive mothers
36. Vertical transmission of human immunodeficiency virus is correlated with the absence of high-affinity/avidity maternal antibodies to the gp120 principal neutralizing domain
37. Mother-to-child transmission of human immunodeficiency virus type 1: Correlation with neutralizing antibodies against primary isolates
38. Failure of a human immunodeficiency virus immune globulin to protect chimpanzees against experimental challenge with HIV
39. agm infection in the African green monkey natural host
40. Passive immunization of Cynomolgus Macaques with immune sera or a pool of neutralizing monoclonal antibodies failed to protect against challenge with SIVmac251
41. Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV-infected women with advanced disease: Results of Pediatric AIDS Clinical Trials Group Protocol 185
42. Use of human immunodeficiency virus (HIV) human hyperimmune immunoglobulin in HIV type 1-infected children (Pediatric AIDS clinical trials group protocol 273)
43. Beta2-microglobulin, HIV-1 p24 antibody and acid-dissociated HIV-1 p24 antigen levels: Predictive markers for vertical transmission of HIV-1 in pregnant Ugandan women
44. The detection of HIV-1 DNA and p24 antigen in breast milk of HIV-1 infected Ugandan women and vertical transmission